Long-Term Outcomes of Tamoxifen Citrate Therapy and Histo- and Immunopathological Properties in Riedel Thyroiditis.
Immunoglobulin G4-related disease
Intercellular adhesion molecule-1
Plasmablast
Riedel thyroiditis
Tamoxifen citrate
Transforming growth factor beta
Journal
European thyroid journal
ISSN: 2235-0640
Titre abrégé: Eur Thyroid J
Pays: England
ID NLM: 101604579
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
24
06
2020
accepted:
04
10
2020
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
29
6
2021
Statut:
ppublish
Résumé
Riedel thyroiditis (RT) is a rare form of thyroiditis; thus, data about the disease course and treatment options are limited. Therefore, we aimed to assess the clinical, serological, radiological, and histopathological features, as well as short- and long-term follow-up of RT patients under glucocorticoid (GC) and tamoxifen citrate (TMX). Parameters related to IgG4-related diseases (IgG4-RD) were also investigated. Eight patients with RT diagnosed between 2000 and 2019 were enrolled. Data were collected in a retrospective and prospective manner. The diagnosis was confirmed with histopathological features in all patients. Results of the treatment with GCs on short- to mid-term, followed by TMX in the long term, were evaluated. The mean age at diagnosis was 40.5 ± 6.8 years; female predominance was observed (F/M:7/1). Parameters related to IgG4-RD, like increase in IgG4 serum levels, total plasmablast counts, and IgG4+ plasmablasts, were negative in most of our patients in both active and inactive states of the disease. Likewise, an increased ratio of IgG4/IgG-positive plasma cells >40% could only be observed in 2 cases. GCs followed by TMX were given to the patients with an over-all median follow-up time of 67 (8-216) months. All the patients considerably improved clinically and had a reduction in the size of the mass lesion on GCs, followed by TMX therapy. None of the patients had a recurrence under TMX therapy for a median period of 18.5 (7-96) months. Even though RT is suggested to be a member of IgG4-RD, serologic or histological evidence of IgG4 elevation or positivity is only useful for diagnosis and follow-up of RT. The diagnosis should be based on clinical and radiological evidence and confirmed by histopathology. GCs are effective for initial treatment, and TMX is a successful and safe therapeutic option for long-term maintenance therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Riedel thyroiditis (RT) is a rare form of thyroiditis; thus, data about the disease course and treatment options are limited. Therefore, we aimed to assess the clinical, serological, radiological, and histopathological features, as well as short- and long-term follow-up of RT patients under glucocorticoid (GC) and tamoxifen citrate (TMX). Parameters related to IgG4-related diseases (IgG4-RD) were also investigated.
METHODS
METHODS
Eight patients with RT diagnosed between 2000 and 2019 were enrolled. Data were collected in a retrospective and prospective manner. The diagnosis was confirmed with histopathological features in all patients. Results of the treatment with GCs on short- to mid-term, followed by TMX in the long term, were evaluated.
RESULTS
RESULTS
The mean age at diagnosis was 40.5 ± 6.8 years; female predominance was observed (F/M:7/1). Parameters related to IgG4-RD, like increase in IgG4 serum levels, total plasmablast counts, and IgG4+ plasmablasts, were negative in most of our patients in both active and inactive states of the disease. Likewise, an increased ratio of IgG4/IgG-positive plasma cells >40% could only be observed in 2 cases. GCs followed by TMX were given to the patients with an over-all median follow-up time of 67 (8-216) months. All the patients considerably improved clinically and had a reduction in the size of the mass lesion on GCs, followed by TMX therapy. None of the patients had a recurrence under TMX therapy for a median period of 18.5 (7-96) months.
CONCLUSION
CONCLUSIONS
Even though RT is suggested to be a member of IgG4-RD, serologic or histological evidence of IgG4 elevation or positivity is only useful for diagnosis and follow-up of RT. The diagnosis should be based on clinical and radiological evidence and confirmed by histopathology. GCs are effective for initial treatment, and TMX is a successful and safe therapeutic option for long-term maintenance therapy.
Identifiants
pubmed: 34178711
doi: 10.1159/000512017
pii: etj-0010-0248
pmc: PMC8216025
doi:
Types de publication
Journal Article
Langues
eng
Pagination
248-256Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
None of the authors have any potential conflicts of interest associated with this research.
Références
Laryngoscope. 2004 Oct;114(10):1758-60
pubmed: 15454767
Surgery. 1996 Dec;120(6):993-8; discussion 998-9
pubmed: 8957485
Arthritis Rheumatol. 2015 Jul;67(7):1688-99
pubmed: 25809420
Arthritis Care Res (Hoboken). 2010 Sep;62(9):1312-8
pubmed: 20506114
Ther Clin Risk Manag. 2016 Feb 15;12:189-99
pubmed: 26929632
J Clin Endocrinol Metab. 2013 Sep;98(9):3543-9
pubmed: 23824414
Case Rep Med. 2011;2011:709264
pubmed: 21837243
Postgrad Med J. 1997 Dec;73(866):817-9
pubmed: 9497955
Endocrine. 2009 Jun;35(3):297-301
pubmed: 19381890
Ann Rheum Dis. 2015 Jan;74(1):190-5
pubmed: 24817416
Endocrine. 2018 Apr;60(1):185-192
pubmed: 29380231
J Clin Endocrinol Metab. 2011 Oct;96(10):3031-41
pubmed: 21832114
Eur J Endocrinol. 2019 May 1;180(5):R175-R183
pubmed: 30889549
Ann Rheum Dis. 2015 Jan;74(1):14-8
pubmed: 24651618
Endocr J. 2012;59(4):273-81
pubmed: 22133985
Endocr Pract. 2004 Nov-Dec;10(6):483-6
pubmed: 16033720
Endocrinol Diabetes Metab Case Rep. 2018 Feb 09;2018:
pubmed: 29472985
Mod Pathol. 2012 Sep;25(9):1181-92
pubmed: 22596100
J Endocrinol Invest. 1995 Apr;18(4):305-7
pubmed: 7560814
Pancreas. 2014 Jul;43(5):704-7
pubmed: 24632552
Thyroid. 2011 Jul;21(7):765-72
pubmed: 21568724
Endocr J. 2015;62(8):725-31
pubmed: 26052139
Thyroid. 2010 Jan;20(1):105-7
pubmed: 20067381
Autoimmun Rev. 2015 Oct;14(10):914-22
pubmed: 26112170
Br J Clin Pharmacol. 1998 Jun;45(6):608-12
pubmed: 9663819